ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项非随机化的自然病史非治疗研究，总共将在美国和加拿大的大约50个地点招募800名受试者，其中包括200名正常对照组、400名MCI患者和200名轻度AD患者进行纵向随访。每个网站的目标是招募8名轻度认知障碍患者，4名阿尔茨海默病患者和4名健康的老年对照组。 ADNI的主要目标是：1.开发改进的方法，以导致统一 获取阿尔茨海默病(AD)、轻度认知障碍(MCI)和老年对照组患者的纵向、多部位MRI和PET数据的标准。 2.获取描述大脑结构和新陈代谢纵向变化的普遍可访问的数据存储库。同时，获取临床认知和生物标记物数据，以验证成像替代物。 3.开发在涉及这些患者的试验中提供最大功率以确定治疗效果的方法。 4.根据统计分析部分概述的临床和生物标记物数据测试一系列假设。 假设： A.2.假设检验 这一倡议的主要目标是收集数据，而不是分析数据。除了进行临床首创，我们还将基于临床和生物标记物数据测试几个假说。下面列出了几个例子： 1.从MCI到AD的转换率平均为10-15%/年。 2.逻辑记忆和载脂蛋白E(APOE)epsilon 4(APOE4)状态的基线分数将预测从MCI到AD的转换。 3.在预测从MCI到AD的转变时，全球功能指标，如日常生活活动能力，将比神经心理学指标更敏感。 4.从MCI回交到正常的比率将非常低 人口。 5.血浆中的异前列腺素a)与疾病的严重程度有关，b)水平越高，下降的速度越快。 6.海马体积和后扣带回葡萄糖代谢率可预测MCI向AD的转归和下降的速度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a non-randomized natural history non-treatment study in which a total of 800 subjects including 200 normal controls, 400 individuals with MCI, and 200 subjects with mild AD will be recruited at approximately 50 sites in the United States and Canada for longitudinal follow up. Each site's goal will be to recruit 8 subjects with Mild Cognitive Impairment, 4 subjects with Alzheimer's disease and 4 Healthy Elderly Controls. The major goals of the ADNI are to: 1. Develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and elderly controls. 2. Acquire a generally accessible data repository which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical cognitive and biomarker data for validation of imaging surrogates. 3. Develop methods which will provide maximum power to determine treatment effects in trials involving these patients. 4. Test a series of hypotheses based on the clinical and biomarker data as outlined in the statistical analysis section. Hypothesis: A.2. HYPOTHESIS TESTING The major goal of this initiative is the collection of data rather than its analysis. In addition to carrying out the clinical initiative, we will test several hypotheses based on the clinical and biomarker data. A few examples are listed below: 1. Rates of conversion from MCI to AD will average 10-15%/year. 2. Baseline scores on logical memory and apolipoprotein E (APOE) epsilon 4 (APOE4) status will predict conversion from MCI to AD. 3. Measures of global functioning such as activities of everyday living will be more sensitive than neuropsychological measures for predicting conversion from MCI to AD. 4. The rate of backcrossing from MCI to normal will be extremely low for this population. 5. Plasma isoprostanes will a) be related to disease severity and b) higher levels will predict a faster rate of decline. 6. Hippocampal volume and posterior cingulate glucose metabolic rate will predict rate of decline and conversion from MCI to AD.